CA2470519C — Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
Assigned to Merck and Co Inc · Expires 2009-11-17 · 16y expired
What this patent protects
Pyrrole compounds selected from the group consisting of 3-(1-pyridin-2-yl-1H-pyrrol-3-yl)benzonitrile; 2-[3-(3-chlorophenyl)-1H-pyrrol-1-yl]pyridine; 2-[3-(3-methoxyphenyl)-1H-pyrrol-1-yl]pyridine; 3-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 2-{1-[3-(trifluoromethyl)phenyl]-1H…
USPTO Abstract
Pyrrole compounds selected from the group consisting of 3-(1-pyridin-2-yl-1H-pyrrol-3-yl)benzonitrile; 2-[3-(3-chlorophenyl)-1H-pyrrol-1-yl]pyridine; 2-[3-(3-methoxyphenyl)-1H-pyrrol-1-yl]pyridine; 3-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 2-{1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}pyridine; 2-[1-(3,5-dichlorophenyl)-1H-pyrrol-3-yl]pyridine; 2-[1-(3-methylphenyl)-1H-pyrrol-3-yl]pyridine; 2-[1-(3-methoxyphenyl)-1H-pyrrol-3-yl]pyridine; 3-[3-(1,3-thiazol-2-yl)-1H-pyrrol-1-yl]benzonitrile; 3-fluoro-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-(3-bromo-4-pyridin-2-yl-1H-pyrrol-1-yl)-5-fluorobenzonitrile; 3-fluoro-5-(3-methyl-4-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-(3-chloro-4-pyridin-2-yl-1H-pyrrol-1-yl)-5-fluorobenzonitrile; 3-fluoro-5-[3-(1H-pyrazol-1-yl)-1H-pyrrol-1-yl]benzonitrile; 2-chloro-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine; 2-(pyridin-3-yloxy)-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine; 2-chloro-4-methyl-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine; 3-chloro-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 2-{1-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-pyrrol-3-yl} pyridine; 3-bromo-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-methyl-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-fluoro-5-[3-(1,3-thiazol-2-yl)-1H-pyrrol-1-yl]benzonitrile; and pharmaceuticallyacceptable salts thereof, are characterized by being substituted directly with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, and are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.